Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: A preliminary approach

Abstract

Background and Aims:Egy-Score is a new noninvasive score for prediction of severe hepatic fibrosis in patients with chronic liver diseases. The aim of this study was to validate Egy-Score as a noninvasive score for predicting stage of hepatic fibrosis in a group of Egyptian chronic hepatitis C patients.Patients and Methods:One hundred Egyptian patients with chronic hepatitis C were enrolled. Mean age was 40.25 ± 9.39 years. They were subjected to CA19-9, alpha-2-macroglobulin, total bilirubin, platelet count and albumin, liver biopsy, and histopathological staging of hepatic fibrosis according to METAVIR scoring system as part of their assessment for treatment. Egy-Score was calculated according to the following formula: Egy-Score = 3.52 + 0.0063 × CA19-9 + 0.0203 × age + 0.4485 × alpha-2-macroglobulin + 0.0303 × bilirubin – 0.0048 × platelet – 0.0462 × albumin. Egy-Score results were correlated to the stage of hepatic fibrosis.Results:Egy-Score correlates positively with the stage of hepatic fibrosis (F0–F4). Egy-Score was able to differentiate significant hepatic fibrosis, severe hepatic fibrosis, and cirrhosis accurately. Cutoff values of Egy-Score were 2.91850 (for significant fibrosis), 3.28624 (for severe fibrosis), and 3.67570 (for cirrhosis). Sensitivity, specificity, and areas-under-ROC curve (AUROCs) were 75.8%, 68.42%, and 0.776 (for significant fibrosis “≥F2”), 91.67%, 77.63%, and 0.875 (for severe fibrosis “≥F3”), and 81.82%, 86.52%, and 0.874 (for cirrhosis “F4”), respectively.Conclusion:Egy-Score is a useful noninvasive panel of surrogate biomarkers that could accurately predict different stages of hepatic fibrosis in patients with chronic hepatitis C.

Comparing the efficiency of Fib‐4, Egy‐score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C

“…In the current study Egy‐score was able to diagnosis significant fibrosis (≥F2) at cutoff value ≥4.73 with 63% sensitivity and 67% specificity. Moreover our results showed less sensitivity and specificity in the detection of significant hepatic fibrosis (≥F2) than the original validation study of the Egy‐score that showed sensitivity of 75.8% and specificity of 68.42% at cut off 2.9 …”

Performance of a calculator for diagnosing the cause of liver damage

“…"Egy-Score" has been developed for the noninvasive assessment of hepatic fibrosis and cirrhosis. Egy-Score has shown good sensitivity, specificity, PPVs and NPVs, and AUROCs for predicting significant fibrosis (≥ F2), severe hepatic fibrosis (≥ F3), and cirrhosis (F4) [15]. Liver stiffness measurement (LSM) can be used to assess liver fibrosis in patients with CH.…”